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Abstract
Alcohol consumption is causally linked to several cancers but the evidence for stom-
ach cancer is inconclusive. In our study, the association between long-term alcohol
intake and risk of stomach cancer and its subtypes was evaluated. We performed a
pooled analysis of data collected at baseline from 491 714 participants in the
European Prospective Investigation into Cancer and Nutrition and the Melbourne
Collaborative Cohort Study. Hazard ratios (HRs) and 95% confidence intervals (CIs)
were estimated for incident stomach cancer in relation to lifetime alcohol intake and
group-based life course intake trajectories, adjusted for potential confounders includ-
ing Helicobacter pylori infection. In all, 1225 incident stomach cancers (78% noncardia)
were diagnosed over 7 094 637 person-years; 984 in 382 957 study participants
with lifetime alcohol intake data (5 455 507 person-years). Although lifetime alcohol
intake was not associated with overall stomach cancer risk, we observed a weak posi-
tive association with noncardia cancer (HR = 1.03, 95% CI: 1.00-1.06 per 10 g/d
increment), with a HR of 1.50 (95% CI: 1.08-2.09) for ≥60 g/d compared to 0.1 to
4.9 g/d. A weak inverse association with cardia cancer (HR = 0.93, 95% CI: 0.87-1.00)
was also observed. HRs of 1.48 (95% CI: 1.10-1.99) for noncardia and 0.51 (95% CI:
0.26-1.03) for cardia cancer were observed for a life course trajectory characterized
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by heavy decreasing intake compared to light stable intake (Phomogeneity = .02). These
associations did not differ appreciably by smoking or H pylori infection status. Limiting
alcohol use during lifetime, particularly avoiding heavy use during early adulthood,
might help prevent noncardia stomach cancer. Heterogeneous associations observed
for cardia and noncardia cancers may indicate etiologic differences.
K E YWORD S
cardia cancer, EPIC, lifetime alcohol intake, MCCS, noncardia cancer, stomach cancer
1 | INTRODUCTION
Stomach cancer is the fifth most common cancer with an estimated
1 033 701 incident cases (5.7% of all cancers) worldwide in 2018.1 Due
to its high fatality, it is the third leading cause of death from cancer,1
with modest survival even in high-income countries.2 The absence of
specific symptoms or a marker for early detection often leads to diagno-
sis when the tumor is already locally advanced or metastatic. Most
stomach cancers are potentially preventable: for example, 77% of stom-
ach cancer deaths and 65% of cases in Australia in 2013 were estimated
to be attributable to modifiable risk factors.3 The vast majority of stom-
ach cancers are known to be associated with infectious agents such as
the bacterium Helicobacter pylori and Epstein-Barr virus4; cigarette
smoking and industrial chemical exposure are established risk factors
while other modifiable lifestyle factors, including alcohol use, consump-
tion of processed meat, foods preserved by salting, and obesity, are clas-
sified as probable causes of stomach cancer.5
Alcohol drinking caused an estimated 3 million deaths globally
(5.3% of all deaths) and an estimated 400 000 deaths from cancer
(representing 4.2% of all cancer deaths) in 2016.6 Ethanol in alcoholic
beverages and its metabolites are causally linked to cancers of the oral
cavity, pharynx, larynx, esophagus (squamous-cell carcinoma), liver,
colorectum and female breast.7 A role for alcohol use in the etiology
of stomach cancer is plausible but the epidemiological evidence
remains equivocal.5,8 Most evidence from prospective studies is based
on consumption data that refer to the time of study recruitment, that
is, alcohol intake at baseline. The baseline intake might not be repre-
sentative of participants' consumption during earlier age periods, par-
ticularly for heavy drinkers who had reduced alcohol consumption.
In our study, we estimated associations for baseline and lifetime
alcohol use with risk of stomach cancer and its subtypes, using retro-
spective information on consumption at various ages before recruit-
ment in two large prospective studies.
2 | MATERIALS AND METHODS
A pooled analysis of 491 714 participants in the European Prospective
Investigation into Cancer and Nutrition (EPIC) and the Melbourne Col-
laborative Cohort Study (MCCS) was conducted.
2.1 | European prospective investigation into
cancer and nutrition
2.1.1 | Participants
EPIC is a multicenter prospective cohort study of 521 324 partici-
pants (70.6% women), mostly of Caucasian descent, aged 35 to
70 years when enrolled, predominantly during 1992to 1998, designed
to investigate the relationship among dietary habits, nutritional status
and various lifestyle/environmental factors and cancer incidence.9
EPIC has 23 centers in 10 European countries (Denmark, France,
Greece, Germany, Italy, the Netherlands, Norway, Spain, Sweden and
What's new?
Alcohol consumption has been causally linked to several can-
cers, but results for stomach cancer have been inconclusive.
In this large, international study, the authors found a positive
association between long-term, heavy drinking and non-
cardia stomach cancer. This association persisted when data
were adjusted for potentially confounding factors such as
smoking, body mass index, and Helicobacter pylori infection.
A weak inverse association was observed with cardia cancer,
suggesting that there may be etiologic differences between
non-cardia vs. cardia subtypes.
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the United Kingdom). Eligible participants gave written informed con-
sent. Ethical review boards from the International Agency for
Research on Cancer and local centers participating in EPIC approved
the study. Participants were excluded if they had a diagnosis of cancer
before recruitment (n = 25 184), had no follow-up information
(n = 4172), no baseline questionnaire data (n = 6259), had extreme
energy intake (n = 9573) or were missing data on the covariates
modeled (n = 23 178). Of the remaining 452 958 (86.9% of the total
cohort) participants, 108 461 (24.0%) had no information on lifetime
alcohol intake (Figure 1).
2.1.2 | Data collection
Diet over the 12 months before enrolment was measured by validated
country-specific dietary questionnaires9 designed to capture local die-
tary habits.10 Most centers adopted a self-administered dietary ques-
tionnaire with 88 to 266 food items. Baseline height and weight (self-
reported in France, Norway and the UK Oxford center, measured
elsewhere), alcohol intake, smoking status, occupational physical
activity and medical history were collected with questionnaires. H
pylori status was determined in nested case-control studies on stom-
ach cancer11 by using a combination of ELISA (Pyloriset EIA-GIII kit;
Orion Diagnostics) and immunoblotting12 assays in plasma collected
at baseline. Cases and controls were matched on age group, sex,
center and date of blood collection. Details on establishing
H pylori-seropositivity have been published previously.11
2.1.3 | Assessment of alcohol intake
Alcohol intake at baseline was estimated from validated dietary
questionnaires where participants reported the number of standard
glasses of wine, beer, cider, sweet liquor, distilled spirits and forti-
fied wines they consumed daily or weekly during the 12 months
before recruitment.9,10 For each participant, an average daily alco-
hol intake expressed in grams per day was calculated based on the
standard glass volume and ethanol content for each type of alco-
holic beverage for each country using information collected
through 24-hour dietary recalls from a subgroup of the cohort.13,14
Study participants also reported their alcohol consumption at
20, 30, 40 and 50 years of age (as appropriate for age at base-
line).15 The average lifetime alcohol intake was calculated as a
weighted average of intakes at different ages with weights equal to
the time of exposure to alcohol at different ages.16 Information on
adult lifetime alcohol intake was available for approximately 76% of
participants.16
2.1.4 | Cohort follow-up and ascertainment of
cases and deaths
Cases were identified from population cancer registries except in
France, Germany, Greece and Naples (Italy), where a combination of
different methods, including accessing health insurance records,
hospital-based cancer and pathology registries and active follow-up
n = 2 757 excluded 0 6 259 n = 68 366 excluded 
n = 108 757 excluded
n = 42 970 excluded
MCCS EPIC
984 stomach cancers diagnosed in 382  957 
participants available for lifetime alcohol analysis





N = 38 756 included
N = 41 513 enrolled into MCCS
Reason for exclusion:
1 Prevalent cancer at enrolment
2 No follow-up data
3 No baseline questionnaire data
4 Extreme energy intake
5 Missing alcohol intake data
6 Missing data on covariates
N = 521 324 enrolled into EPIC
1 225 stomach cancers (EPIC = 1 003, 81.9%;
MCCS = 222, 18.1%) diagnosed in 491 714 
participants with baseline alcohol intake data
Reason for exclusion:
Missing lifetime alcohol intake data
948 stomach cancers diagnosed in 339 987 
participants available for trajectory analysis
Reason for exclusion:
Did not have at least three intake
data points
N = 452 958 included
F IGURE 1 Flow diagram showing selection of participants. EPIC, European Prospective Investigation into Cancer and Nutrition; MCCS,
Melbourne Collaborative Cohort Study
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(participant tracking), were used. Incident primary invasive stomach
cancer cases were defined as those with code C16 according to the
10th revision of the International Classification of Diseases (C16.0,
cardia; C16.1, fundus of stomach; C16.2, body of stomach; C16.3,
pyloric antrum; C16.4, pylorus; C16.5, lesser curvature of stomach,
not classifiable to C16.1-C16.4; C16.6, greater curvature of stomach,
not classifiable to C16.0-C16.4; C16.8, overlapping lesion of stomach;
C16.9, stomach unspecified). Histologic type17 (diffuse-type [mor-
phology codes 8145/3, 8490/3, 8142/3], intestinal-type [morphology
codes 8144/3, 8211/3, 8260/3, 8480/3, 8481/3, 8140/3]; other
morphology codes classified as mixed/other/unknown)18,19 and ana-
tomical location (cardia C16.0, noncardia C16.1-6, overlapping/
unspecified C16.8-9) were determined; a panel of pathologists
reviewed original pathology reports, tumor slides and paraffin blocks
for a subset of cases.20
2.2 | Melbourne Collaborative Cohort Study
2.2.1 | Participants
The MCCS is a prospective cohort study of 41 513 people (58.9%
women; 99.2% aged 40-69 years), all of white European descent, rec-
ruited during 1990to 1994 in Melbourne, Australia.21 The study pro-
tocol was approved by the Cancer Council Victoria Human Research
Ethics Committee. Participants gave written informed consent to par-
ticipate and for investigators to obtain access to their medical records.
For this analysis, we selected participants who did not have a previous
diagnosis of cancer at enrolment (n = 39 973). Participants reporting
extreme values of total energy intake (<1st percentile and >99th per-
centile) (n = 804) or missing alcohol consumption data (n = 376), or
missing data on any of the covariates modeled (n = 37) were excluded,
leaving 38 756 (93.4% of the total cohort) eligible for this analysis;
only 296 (0.8) were missing information on lifetime alcohol intake
(Figure 1).
2.2.2 | Baseline data collection
Structured interview schedules were used to obtain information on
potential risk factors including age, sex, country of birth, education,
previous medical conditions and lifestyle behaviors (including cigarette
smoking, physical activity and alcohol intake). A 121-item food fre-
quency questionnaire was used to collect dietary information.22
Height was measured to 1 mm with a stadiometer, and weight to
100 g using digital electronic scales. Residential address was used to
classify participants into quintiles of an area-based measure of socio-
economic status. H pylori status was determined in nested case-
control studies of stomach cancer23,24 by using immunoblotting12
assays in plasma collected at baseline. Cases and controls were mat-
ched on year of birth, sex and country of birth. Details on establishing
H pylori-seropositivity have been published previously for MCCS24
participants.
2.2.3 | Assessment of alcohol intake
Participants were asked at baseline if they had ever drunk at least
12 alcoholic drinks in a year. Those who had (“nonlifetime abstainers”)
were then asked about their usual frequency of consumption and
usual quantity consumed per drinking occasion for beer, wine and
spirits separately during 10-year age periods commencing at age
20, up to the decade of their age at baseline attendance. Usual intake
within each age period in grams per day for each beverage type was
calculated by multiplying intake frequency by quantity and standard
amount of alcohol per container using Australian food composition
tables.25 The alcohol intake for each age period in grams per day was
calculated as the sum of intake from the three beverage types. The
baseline alcohol intake in grams per day was obtained from intake for
the age period encompassing baseline. Beverage-specific total intakes
within age periods were summed to obtain total lifetime intakes in
grams. The average lifetime alcohol intake in grams per day was
derived by dividing the total lifetime intake by the total number of
days within the age intervals up to baseline attendance.
2.2.4 | Cohort follow-up and ascertainment of
cases and deaths
Cases and vital status were ascertained through the Victorian Cancer
Registry (VCR), the Victorian Registry of Births, Deaths and Marriages,
the National Death Index and the Australian Cancer Database. The
outcome was defined as a histopathological diagnosis of primary
invasive adenocarcinoma of the stomach, coded following the 3rd
Revision of the International Classification of Diseases for Oncology
(ICD-O-3) as C16. Tumor histopathology and anatomical site were
obtained from the VCR.
2.3 | Statistical analysis
The association between alcohol intake and stomach cancer was
examined after pooling EPIC and MCCS data. Cox regression26 was
used to estimate hazard ratios (HRs) and 95% confidence intervals
(CIs) with age as the time scale and stratified by year of birth (<1925,
5-year categories from 1925 to 1964, ≥1965) and study center (EPIC)
or country of birth (MCCS, Australia/New Zealand/United Kingdom
or Italy/Greece). The age when the baseline questionnaire was ret-
urned (EPIC) or of baseline attendance (MCCS) was defined as the age
when follow-up started. Follow-up was censored at diagnosis of any
first primary cancer, death, emigration or end of follow-up (center-
specific censor date for EPIC; 31 January 2017 for MCCS).
Alcohol intake was modeled as a continuous variable (per 10 g/d
increment in intake, the size of a standard drink in Australia) and for
intake categories derived using the following cut-points: nondrinkers,
0.1-4.9, 5-14.9, 15-29.9, 30-59.9, ≥60 g/d for total alcohol; non-
drinkers, 0.1-4.9, 5-14.9, 15-29.9, ≥30 g/d for beer and wine; and
nondrinkers, 0.1-4.9, 5-14.9, ≥15 g/d for spirits. Consistently
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throughout our study, the 0.1-4.9 g/d category (ie, very light or occa-
sional drinkers) was used as the reference group. Nearly 78% of the eli-
gible study participants (n = 382 957) were included in analyses for
lifetime alcohol intake (Figure 1). Based on this information, 35% of non-
drinkers at baseline were former drinkers. A causal diagram (directed
acyclic graph) and existing evidence5 guided the inclusion of con-
founding variables in multivariable models: sex, education (primary
school, technical school, secondary school, university), cigarette smoking
(never, former >10 years since quitting, former ≤10 years since quitting;
current <20 cigarettes/d, current ≥20 cigarettes/d, other), body mass
index (kg/m2), intake of total red and processed meat (g/d), fruit intake
(g/d) and total energy from food not including alcoholic beverages
(Kcal/d) (Supplementary Figure 1). The evaluation of H pylori infection
status as a confounder for noncardia cancer is described below.
We also examined associations with patterns of lifetime alcohol
intake based on a semiparametric group-based trajectory model.27,28
This model is an application of finite mixture modeling which assumes
the study sample is composed of a mixture of groups following homog-
enous courses.27 Longitudinal alcohol intake data were fitted as a mix-
ture of several latent trajectories in a censored normal model, allowing
for the lower (zero g/d) and upper intake (capped at 100 g/d) limits,
with a polynomial function for age.28 We used the Bayesian informa-
tion criterion and the log Bayes factor to select optimal shapes and
number of trajectory groups through a two-stage approach.27 First, the
number of groups was determined assuming all trajectory groups were
cubic functions of age. Second, the preferred order of the polynomial
(ie, quadratic or cubic) for each trajectory was determined. Participants
were assigned to the group for which their posterior predicted proba-
bility calculated from the final model was largest. Model adequacy was
evaluated using recommended diagnostic measures: average posterior
probability of assignment for each group of 0.7 or higher; odds of cor-
rect classification of 5.0 or higher; the proportion of a sample assigned
to a certain group close to the proportion estimated from the model;
and a reasonably narrow CI around each trajectory.27 Participants with
at least three intake data points (n = 339, 987; 69% of the eligible
study participants) were included (Figure 1). We repeated this analysis
excluding former drinkers at baseline.
To test for heterogeneity in the HRs between anatomical subsites
(cardia and noncardia) and histologic subtypes (diffuse-type and
intestinal-type) of stomach cancer, Cox regression models were fit in
competing risks analysis.29 An augmented data set was created where
the initial data set was replicated a number of times equal to the dif-
ferent subtypes. In each replicated data set, the competing subtype
was set to censored observations and the analyses were stratified by
the endpoint type.30 A histopathologic validation of a subset of EPIC
data (n = 373 cases) found that all cancers classified as “mixed site,”
and over half of the cancers classified as “gastric unknown,” were in
fact noncardia cancers.20 Because most tumors with site codes C16.8
(overlapping) and C16.9 (unspecified) are noncardia cancers, we classi-
fied tumors with site codes C16.1-6, C16.8 and C16.9 as noncardia as
has been done previously.31,32
A dose-response relationship between lifetime alcohol intake and
stomach cancer incidence was examined by comparing models that
included alcohol as a linear term and with restricted cubic splines (with
five knots placed at 0.1, 5, 30, 60 and 100 g/d), with upper intake
capped at 100 g/d.33 We evaluated potential effect modification by
sex, cigarette smoking and body mass index by including interaction
terms with lifetime alcohol intake (continuous). We assessed the inter-
action term with the likelihood ratio test. Interaction with H pylori
infection status and confounding due to it were evaluated for non-
cardia cancer using pooled data from EPIC11 and MCCS23,24 nested
case-control studies (374 noncardia cancer cases and 1163 controls).
Conditional logistic regression models included education, cigarette
smoking, body mass index, meat intake, fruit intake and energy intake
from food.
Sensitivity analyses were performed (a) excluding the first 2 years
of follow-up, (b) without adjustment for body mass index and dietary
covariates and (c) by estimating study-specific HRs and pooling study-
specific results using random effects models. Each model was exam-
ined for outliers and influential points. Nested models were compared
using likelihood ratio tests. Tests based on Schoenfeld residuals
showed no departure from the proportional hazard assumptions. All
statistical tests were two-sided, and statistical analyses were
performed using Stata 16.1 (StataCorp, College Station, TX).
3 | RESULTS
Characteristics of the 491 714 participants are described in Table 1.
EPIC contributed 92.1% of participants with a mean follow-up of
14 years and MCCS had a mean follow-up of 20 years, with 1225
incident stomach cancer cases from both studies combined (cardia
C16.0 = 274, 22.4%; noncardia = 951, 77.6% including
C16.1-16.6 = 484, 39.5% and C16.8-16.9 = 467, 38.1%). Over two-
thirds of participants were women, but more cases (n = 690, 56.3%)
were men. The mean age at recruitment was 51.4 years; cases were
diagnosed at a mean age of 67 years. Stomach cancer incidenced by
country for EPIC and by country of birth for MCCS are reported in
Supplementary Table 1. EPIC data for France and Norway only
included women hence their lower incidence.
About one-third of participants was either lifetime abstainers or
drank less than 5 g/d, and 2.2% reported a lifetime intake of ≥60 g/d
(Table 1). Although the proportion of lifetime abstainers was higher
for MCCS (28.6%) than EPIC (6%), the median lifetime alcohol intake
for drinkers was higher for the MCCS than EPIC (Supplementary
Table 2). Male drinkers consumed more alcohol during their lifetime
than female drinkers (median intakes 18.4 and 5.1 g/d, respectively)
(Supplementary Table 2).
3.1 | Lifetime alcohol intake and stomach cancer
incidence
Lifetime alcohol intake was not associated with overall stomach can-
cer incidence (HR = 1.01, 95% CI: 0.99-1.04 for a 10 g/d increment)
(Table 2). The HR for a lifetime intake of 60 g/d or greater was 1.19
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(95% CI: 0.88-1.61), compared to 0.1 to 4.9 g/d. Models with cubic
splines did not fit better than models with a single linear term for life-
time intake (P = .94). In analyses for subsites of the stomach, a 10 g/d
increment in lifetime alcohol intake was weakly associated with
increased incidence of noncardia cancer (HR = 1.03, 95% CI:
1.00-1.06; P = .03) and showed a weak inverse association with can-
cer of the gastric cardia (HR = 0.93, 95% CI: 0.87-1.00 for a 10 g/d
increment; P = .06) (Phomogeneity < .01) (Table 2; Supplementary
Figure 2). Using intake categories, for a lifetime intake of 60 g/d or
greater, the HR was 1.50 (95% CI: 1.08-2.09), compared to 0.1-4.9 g/
d, for noncardia cancer; the corresponding HR for cardia cancer was
0.48 (95% CI: 0.23-1.01) (Phomogeneity = .03) (Table 2). When stratified
by sex, HRs were similar for men and women for overall and non-
cardia stomach cancer (Pinteraction = .71 and Pinteraction = .60,
TABLE 1 Characteristics of study participants from the European Prospective Investigation into Cancer and Nutrition (EPIC) and the
Melbourne Collaborative Cohort Study (MCCS)
EPIC MCCS Total
Age at recruitment (years), mean (range)a 51.1 (33.3-65.7) 55.2 (41.5-68.3) 51.4 (34.2-66.3)
Sex, n (%)
Male 137 138 (30.3) 15 804 (40.8) 152 942 (31.1)
Female 315 820 (69.7) 22 952 (59.2) 338 772 (68.9)
Education, n (%)
Primary school 141 125 (31.2) 7461 (19.3) 148 586 (30.2)
Technical school 104 761 (23.1) 14 746 (38.0) 119 507 (24.3)
Secondary school 95 300 (21.0) 8014 (20.7) 103 314 (21.0)
University 111 772 (24.7) 8535 (22.0) 120 307 (24.5)
Cigarette smoking intensity, n (%)
Never 197 812 (43.7) 22 447 (57.9) 220 259 (44.8)
Former >10 years since quitting 57 609 (12.7) 7618 (19.7) 80 371 (16.3)
Former ≤10 years since quitting 34 106 (7.5) 4312 (11.1) 48 518 (9.9)
Current <20 cigarettes/d 44 206 (9.8) 1986 (5.1) 59 595 (12.1)
Current ≥20 cigarettes/d 72 753 (16.1) 2285 (5.9) 36 391 (7.4)
Other (incomplete, pipes, other) 46 472 (10.2) 108 (0.3) 46 580 (9.5)
Baseline alcohol intake (g/d), n (%)
Abstainer 61 759 (13.6) 15 237 (39.3) 76 996 (15.7)
0.1-4.9 155 372 (34.3) 7290 (18.8) 162 662 (33.1)
5-14.9 120 777 (26.7) 5684 (14.7) 126 461 (25.7)
15-29.9 62 751 (13.9) 5488 (14.2) 68 239 (13.9)
30-59.9 40 957 (9.0) 3883 (10.0) 44 840 (9.1)
≥60 11 342 (2.5) 1174 (3.0) 12 516 (2.5)
Lifetime alcohol intake (g/d), n (%)
Lifetime abstainer 27 370 (6.0) 11 082 (28.6) 38 452 (7.8)
0.1-4.9 120 585 (26.6) 8184 (21.1) 128 769 (26.2)
5-14.9 104 415 (23.0) 8493 (21.9) 112 908 (23.0)
15-29.9 55 552 (12.3) 6065 (15.6) 61 617 (12.5)
30-59.9 27 023 (6.0) 3625 (9.4) 30 648 (6.2)
≥60 9552 (2.1) 1011 (2.6) 10 563 (2.2)
Missing 108 461 (24.0) 296 (0.8) 108 757 (22.1)
Body mass index (kg/m2), mean (range)a 25.4 (19.7-33.2) 26.9 (20.8-35.0) 25.6 (19.8-33.4)
Total red and processed meat intake (g/d), mean
(range)a
75.6 (3.4-168.1) 123.7 (32.5-260.2) 79.4 (4.4-177.7)
Fruit intake (g/d), mean (range)a 238.9 (32.5-571.7) 450.0 (81.8-1041.6) 255.5 (34.3-626.0)
Energy intake from food (Kcal/d), mean (range)a 1994 (1158-3082) 2097 (1117-3501) 2002 (1155-3112)
Total participants, n 452 958 38 756 491 714
aRange = 5th to 95th percentile.
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(B) Hazard ratios for intake patterns
F IGURE 2 A, Patterns of alcohol intake during lifetime according to age at baseline (low stable, blue; light stable, red; moderate increasing,
green; heavy decreasing, yellow) (circles represent average alcohol intake and vertical bars represent variation of alcohol intake between 10th and
90th percentile values at different assessment ages) and B, forest plot of adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) for
overall and site-specific stomach cancer incidence according to alcohol intake pattern for all participants
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respectively), and the inverse association with cardia cancer was
observed in men only (Pinteraction = .02) (Table 3; Supplementary
Table 3).
HRs for lifetime alcohol intake did not differ appreciably in sepa-
rate analyses of stomach cancers of specified noncardia sites
(C16.1-C16.6) and overlapping/unspecified stomach cancers (C16.8
and C16.9) (Supplementary Table 4). Differences in HRs between
diffuse-type and intestinal-type stomach cancer were minimal
(Phomogeneity = .97) (Supplementary Table 5). Baseline alcohol intake
was not associated with incidence of stomach cancer or its subtypes
(Table 2).
3.2 | Alcohol intake trajectories and stomach
cancer incidence
Four patterns of alcohol intake over time, depicting low stable, light
stable, moderate increasing and heavy decreasing intakes, were identi-
fied (Figure 2A). Heavy decreasing intake, compared to light stable
intake, was positively associated with noncardia cancer (HR = 1.48,
95% CI: 1.10-1.99); the corresponding HR for cancer of the gastric
cardia was 0.51 (95% CI: 0.26-1.03) (Phomogeneity = .02) (Figure 2B;
Supplementary Table 6). This finding was consistent after excluding
former drinkers at baseline (Supplementary Table 6).
3.3 | Effect modification
There was no evidence that associations with lifetime alcohol
intake differed between never and ever smokers for overall stom-
ach cancer or by subsite and weak suggestive evidence that the
inverse association for lifetime alcohol intake with cardia cancer
was limited to overweight or obese individuals (Pinteraction = .07)
(Table 3). There was no evidence for an interaction between life-
time alcohol intake and H pylori infection status (Pinteracton = .57;
Table 4). The odds ratio for a 10 g/d increment in lifetime alcohol
intake with adjustment for H pylori infection status was similar to
the HR for noncardia cancer in the main analysis without
adjustment for H pylori infection status.
3.4 | Beverage-specific intakes and stomach
cancer incidence
There was no evidence of associations between individual beverage
types and overall stomach cancer incidence (Supplementary Table 7).
The HRs for a 10 g/d increment in lifetime wine intake for noncardia
and cardia cancers were 1.03 (95% CI: 0.98-1.08) and 0.91 (95% CI:
0.81-1.01), respectively (Phomogeneity = .02) (Supplementary Table 8);
HRs for noncardia cancer were 1.21 (95% CI: 0.83-1.77), 1.36 (95%
CI: 1.01-1.84) and 1.56 (95% CI: 1.11-2.19) for the highest category
for beer (≥30 g/d), wine (≥30 g/d) and spirit (≥15 g/d) respectively,
compared to 0.1 to 4.9 g/d.
3.5 | Sensitivity analyses
The following HRs were observed when estimated study-specific HRs
for a 10 g/d increment in lifetime alcohol intake were pooled using
random effects models, for overall stomach, cardia and noncardia can-
cer, respectively: 1.01 (95% CI: 0.99-1.04), 0.93 (95% CI: 0.86-1.00)
and 1.03 (95% CI: 1.00-1.06), thus displaying very similar estimates
(and corresponding CIs) to aggregate-level data. Associations between
alcohol intake and overall and subtypes of stomach cancer incidence
did not change appreciably when the first 2 years of follow-up were
excluded (Supplementary Tables 9 and 10) or when models were not
adjusted for body mass index and dietary covariates.
4 | DISCUSSION
In our study, we observed a weak positive dose-dependent associa-
tion for lifetime alcohol intake limited to noncardia stomach cancer,
which did not differ appreciably between men and women or by levels
TABLE 4 Odds ratios for noncardia stomach cancer by Helicobacter pylori status for a 10 g/d increment in lifetime alcohol intake for pooled
nested case-control study participants in the European Prospective Investigation into Cancer and Nutrition (EPIC) and the Melbourne
Collaborative Cohort Study (MCCS)
Noncardia stomach cancer cases (%) Controls (%) Median (IQR), g/d OR (95% CI)a Pinteraction
All participants 374 (100) 1163 (100) 9.4 (2.1-24.5) 1.03 (0.97-1.10)
All participantsb 374 (100) 1163 (100) 9.4 (2.1-24.5) 1.03 (0.97-1.10)
By Helicobacter pylori status .57
Helicobacter pylori positive 334 (89.3) 767 (66.0) 9.4 (1.5-26.5) 1.04 (0.98-1.10)
Helicobacter pylori negative 40 (10.7) 396 (34.0) 9.3 (3.2-19.1) 0.98 (0.82-1.19)
Note: Cases and controls matched on age group, sex, center and date of blood collection in EPIC and on year of birth, sex and country of birth in MCCS.
Abbreviations: CI, confidence interval; IQR, interquartile range; OR, odds ratios.
aAdjusted for, education (primary school, technical school, secondary school, university), cigarette smoking (never, former, current), body mass index
(kg/m2), total meat intake (g/d), fruit intake (g/d) and total energy from food (Kcal/d).
bAdditionally adjusted for Helicobacter pylori infection status.
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of smoking, body mass index or H pylori infection status. We identified
four alcohol intake patterns during the life course, with heavy drinking
during early adulthood being associated with higher risk of noncardia
cancer, compared to consistent light drinking. A weak inverse associa-
tion for cancer of the gastric cardia with lifetime alcohol intake was
also observed in men.
Study strengths include the prospective design, comprehensive
assessment of alcohol intake over the life course based on intakes at
different ages, and over 15 years of follow-up on average. Addition-
ally, the large study size with nearly half-a-million study participants
and over one thousand incident stomach cancers enabled the exami-
nation of associations for subtypes and by sex, cigarette smoking and
body fatness and we were also able to study individual alcoholic bev-
erage types as well as heavy consumption. Information on H pylori sta-
tus at baseline was available for subsamples of the studies. Among the
several limitations is the use of self-reported alcohol intake and expo-
sure misclassification, hence bias in HR estimates cannot be ruled out.
We also cannot completely rule out misclassification of stomach can-
cer subtypes, as 38.1% and 19.4% of tumors were not classified for
site and histology, respectively. For instance in European settings and
in Australia, nearly 50% of stomach cancers are coded as overlapping
(C16.8) or unspecified (C16.9) for site,34 due to the difficulty in deter-
mining the origin of large tumors or those in the poorly defined distal
boundary of the gastric cardia.35 We pooled overlapping or
unspecified tumors with noncardia cancer consistent with other large
cohort studies,31,32 raising the possibility of misclassification, but sen-
sitivity analyses showed that the HRs were not affected. In any case,
contamination of overlapping and unspecified tumors by cardia cancer
will move the HR for the pooled noncardia cancer toward the null that
is, the HR will be underestimated.
Alcohol intake is classified as a probable cause of stomach cancer
based on evidence for an association for intakes of 45 g/d or more,
compared to abstention, mostly using data on alcohol intake at
recruitment from case-control studies.5 No association has been
observed for women.5,36 An earlier analysis of the EPIC study found
increased risk of stomach cancer associated with heavy baseline alco-
hol intake37; other prospective studies did not report a similar find-
ing.31,32,38 Similarly, evidence for an association between baseline
alcohol intake and noncardia stomach cancer using prospective data
remains inconclusive.5,37,38 The Shanghai Cohort Study previously
observed an increased risk of stomach cancer associated with long-
term drinking in men, that is, a HR of 1.49 (95% CI: 1.01-2.19) for
those who drank four drinks per day or more for more than 30 years
compared to nondrinkers,39 and also reported a HR of 1.51 (95% CI:
0.99-2.32) for noncardia cancer for heavy drinkers compared to
nondrinkers,39 similar to the present study. The association between
lifetime alcohol intake and noncardia cancer risk was independent of
H pylori infection status in contrast with previous findings40 or
smoking status as in published data.5,41
No previous observational study examined drinking trajectories in
relation to stomach cancer. The association of noncardia cancer with
heavy drinking during early adulthood using trajectories and the asso-
ciation with lifetime alcohol intake in our study are suggestive of early
initiation and chronic progression of carcinogenesis linked to alcohol
and its metabolites.42 Acetaldehyde, the toxic metabolite of ethanol in
alcoholic beverages, is a carcinogen.43 Although the liver plays the
major role in alcohol metabolism, first pass metabolism in the stomach
also produces acetaldehyde,44 predominantly in the gastric mucosa in
the body of stomach45 and more so in males, following high alcohol
concentrations and when the stomach is full.46 The precise mecha-
nisms leading to alcohol-associated noncardia carcinogenesis, none-
theless, are far from being established. Associations of alcohol with
stomach cancer risk may be mediated by retinoid metabolism, leading
to adverse effects on cellular differentiation and apoptosis, the pro-
duction of lipid peroxidation and oxygen free radicals, or by direct cel-
lular injury and gene mutation by enhancing penetration of
carcinogens into cells.5
Cancers of the gastric cardia and noncardia differ substantially in
their patterns of incidence and etiology.47 While noncardia cancer is
more common globally, cardia cancer is becoming increasingly common
in high income countries where central obesity is also increasingly prev-
alent.48 The suggestive inverse association for cardia cancer with life-
time alcohol intake that was limited to men and to overweight or obese
individuals in the present study cannot be explained mechanistically
and could be due to chance. While studies have shown an inverse asso-
ciation for alcohol use with esophageal adenocarcinoma,49 a tumor sim-
ilar to cardia cancer in terms of etiology and response to treatment, the
Continuous Update Project of the World Cancer Research Fund/Ameri-
can Institute for Cancer Research found no evidence of an association.5
A previous meta-analysis comparing drinkers with nondrinkers reported
relative risks of 0.87 (95% CI: 0.74-1.01) and 0.89 (95% CI: 0.76-1.03)
for adenocarcinoma of the esophagus and cardia cancer, respectively.50
Cardia cancers may be more impacted by mis-classification than non-
cardia due to the difficulty in distinguishing tumors that are in
close proximity to each other and tumors that often overgrow the gas-
troesophageal junction.35 In an EPIC subsample, 10% of cardia cancers
were found to be esophageal adenocarcinomas after histopathologic
review.20
In conclusion, lifetime alcohol intake was associated with
increased risk of noncardia stomach cancer, independent of smoking,
body mass index and H pylori infection status. Limiting alcohol use
during lifetime, particularly avoiding heavy use during early adulthood,
might help prevent noncardia stomach cancer.
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